Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers
J. Clin. Invest. Patrick C.H. Hsieh, et al. 116:237 doi:10.1172/JCI25878 [
Go to this article.]
Figure 3Controlled local myocardial delivery of PDGF-BB using injectable self-assembling peptide NFs. (
A) PBS, BSA, PDGF-BB, VEGF-A, bFGF, or angiopoietin-1 (Ang-1) was embedded in NFs, and the binding capacity of NFs to individual protein was determined. (
B) Rat left coronary artery was ligated to induce MI, followed with peptide NF injection in the border zones via 3 different directions. Myocardial protein was extracted from the injected areas, and retention of PDGF-BB, with or without NFs, was assessed using ELISA for human PDGF-BB.
n = 6 for each group; no human PDGF-BB was detected in control animals with NFs alone (data not shown). **
P < 0.001. (
C) Immunohistochemistry of phospho–PDGFR-β (brown) in sections from different groups 14 days after MI. (
D) Immunofluorescence staining of phospho–PDGFR-β in the myocardium after injection of NF/PDGF-BB. Shown is a 14-day section containing papillary muscle. Blue, DAPI; red, α-sarcomeric actinin; green, phospho–PDGFR-β. Scale bar: 5 μm. (
E) Myocardial proteins were extracted 1 and 14 days after MI and subjected to Western blot analyses using antibodies against phospho–PDGFR-β, total PDGFR-β, phospho-Akt, and total Akt.
